Bayer, J&J launch two more late-stage trials of rivaroxaban

03/12/2013 | PharmaTimes (U.K.)

Bayer and Johnson & Johnson are beginning two more late-stage trials of the blood thinner Xarelto, or rivaroxaban, after failing to get the FDA's OK for the treatment of patients with acute coronary syndrome. One trial involves patients with chronic heart failure and significant coronary artery disease. The other will involve patients with nonvalvular atrial fibrillation.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR